Kowa Teva Consolidates Taisho Marketing Operation
This article was originally published in PharmAsia News
Executive SummaryKowa Teva will fully consolidate the marketing division of Taisho Pharmaceutical Industry in July
You may also be interested in...
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.